Evidence map›Paper›PMID 35249006›Full record

ReviewIntervirology2022

Latest Insights on the Diagnostic Approaches and Treatment Strategies of COVID-19.

Sarah S Hassanein, Muhammed R Sharaby, Noran M Tawfik, Suzan A Rashed, Mohamed Adel, Ayat Fayez, Heba Mansour, Haitham M Amer

Open access · goldAbstract readReview
In one paragraph

Review in Intervirology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sarah S HassaneinBasic and Applied Sciences (BAS) Institute, Biotechnology Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.
Muhammed R SharabyBasic and Applied Sciences (BAS) Institute, Biotechnology Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.
Noran M TawfikBasic and Applied Sciences (BAS) Institute, Biotechnology Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.
Suzan A RashedBasic and Applied Sciences (BAS) Institute, Biotechnology Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.
Mohamed AdelBasic and Applied Sciences (BAS) Institute, Biotechnology Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.
Ayat FayezBasic and Applied Sciences (BAS) Institute, Biotechnology Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.
Heba MansourBasic and Applied Sciences (BAS) Institute, Biotechnology Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.
Haitham M AmerVirology Department, Faculty of Medicine Veterinary, Cairo University, Giza, Egypt.
Egypt-Japan University of Science and Technology · EGCairo University · EGSuez Canal University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 has emerged as the most serious pandemic in the 21st century to date. COVID-19 patients may develop various disease symptoms that hinder the accurate clinical diagnosis. SUMMARY: Routine diagnosis of COVID-19 requires complementary investigations, including computed tomography, immunological assays, and molecular assays like real-time RT-PCR, loop-mediated isothermal amplification, metagenomic next-generation sequencing, and clusters of regularly interspaced short palindromic repeats-based assays. Clinically approved antiviral drugs available for the COVID-19 treatment are very limited. The most common measurements that enhance health condition and patients' viability are conservation fluid management, oxygen therapy, and antibiotics. Several therapeutic options have been developed or repurposed to prevent virus replication and/or modulate the immune response against virus infection. These options include various drugs that affect virus entry and membrane fusion, inhibit polymerase and protease activity, suppress the host pro-inflammatory cytokines, and utilize cell therapy approaches. KEY MESSAGES: In this review, we aimed to provide an up-to-date discussion on the current diagnostic options and therapeutic strategies used to control and manage COVID-19 in clinical and point-of-care settings.

Indexed as

COVID-19COVID-19 Drug TreatmentAnti-Bacterial AgentsAntiviral AgentsCytokinesHumansOxygenPeptide HydrolasesSARS-CoV-2Anti-Bacterial AgentsAntiviral AgentsCytokinesOxygenPeptide HydrolasesCoronavirus disease-19Life cycleMolecular diagnosisSARS-CoV-2Therapeutics

Identifiers

PMID35249006
PMCPMC9148896
OpenAlexW4220801011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.